anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide, with 20% of patients presenting with metastatic disease at diagnosis. TGF-β signaling plays a crucial role in various cellular processes, including growth, differentiation, apoptosis, epithelial-mesenchymal transition (EMT), regulation of the extracellular matrix, angiogenesis, and immune responses. TGF-β signals through SMAD proteins, which are intracellular molecules that transmit TGF-β signals from the cell membrane to the nucleus. Alterations in the TGF-β pathway and mutations in SMAD proteins are common in metastatic CRC (mCRC), making them critical factors in CRC tumorigenesis. This review first analyzes normal TGF-β signaling and then investigates its role in CRC pathogenesis, highlighting the mechanisms through which TGF-β influences metastasis development. TGF-β promotes neoangiogenesis via VEGF overexpression, pericyte differentiation, and other mechanisms. Additionally, TGF-β affects various elements of the tumor microenvironment, including T cells, fibroblasts, and macrophages, promoting immunosuppression and metastasis. Given its strategic role in multiple processes, we explored different strategies to target TGF-β in mCRC patients, aiming to identify new therapeutic options.
FIELD: medicine. ^ SUBSTANCE: claimed group of inventions relates to medicine, namely, to angiology, and deals with excitation of vasodilation of peripheral blood vessels. For this purpose introduced is composition which includes efficient amount of polyphenols, characterised by general formula I. Composition is introduced in form of cocoa extract, solid cocoa or cocoa powder. ^ EFFECT: invention ensures dilatation of peripheral vessels through NO - independent mechanism, which can be used in case of vascular endothelium dysfunction. ^ 20 cl, 1 tbl, 1 ex
The invention belongs to the technical field of medicines, and particularly relates to a high-efficiency low-toxicity anticancer combined medicine and a pharmaceutical composition. The invention provides an application of guanidine compounds combined with piperlonguminine in preparation of anticancer drugs. Wherein the guanidine compound is selected from metformin. The combination of the present invention has better anticancer activity than a single dose of the drug. Compared with platinum chemotherapeutics, the combined administration scheme has the same tumor killing effect, and has no obvious effect on body weight, immune system, liver function, kidney function and the like of mice, which shows that the toxic and side effects of the combination are obviously weaker than those of the platinum chemotherapeutics. Therefore, the combined drug administration scheme of the invention has good application prospect.
Various embodiments of health supplements for mammals are disclosed. The health supplement consists of one or more metabolite ingestion components; anti-inflammatory components; and oral absorption components. The metabolite ingestion component includes green-lipped mussel powder in an amount between 1-5 mg/kg of body weight. The anti-inflammatory component includes cinnamon powder in an amount between 0.1-1. mg/kg of body weight; ascorbic acid powder; turmeric powder present in an amount between 0.1-1.0 mg/kg of body weight; Piper nigrum powder in an amount between 0.05-0.2 mg/kg of body weight; and the oral absorption component includes diatomaceous earth powder and molasses powder. The metabolite ingestion component includes sea cucumber powder, sodium hyaluronate powder, methylsylfonylmethane powder, and creatine monohydrate powder. The anti-inflammatory component includes Boswellia serrata powder, Harpagophytum procumbens powder, and calcined curcumin powder. The oral absorption component includes Lactobacillus probiotic powder; and calcined dolomite powder.
Participants (healthy adults aged \>=18 to \<= 55 years) will receive Ad26.COV2.S as a single vaccination in the primary regimen or matching Placebo on Day 1 and Day 57. At unblinding visit, post EUA, conditional licensure, or approval for the single dose regimen of Ad26.COV2.S vaccine, participants initially receiving placebo will be offered to receive a single dose of Ad26.COV2.S. If they choose not to receive Ad26.COV2.S they will be asked to continue to be followed in this study. All eligible participants who have previously received any COVID-19 vaccination (as primary regimen or additional dose) if the last vaccination was \>=6 months ago will be offered to receive a single ad hoc booster dose of Ad26.COV2.S. If they choose not to receive ad-hoc booster dose they will be asked to continue to be followed in this study.
Group A will supplement using the bottle. The mother will breastfeed as frequently as the neonate's physician allows. When the physician recommends supplementation, the mother will supplement using the bottle per standard of care. The mother will breastfeed for up to 25 minutes and then will offer a bottle to supplement breastfeeding for at least 5 minutes. Time at the breast and with the bottle might vary based on the neonate's ability to stay awake at the breast and to sustain a latch at the breast. The type of supplementation will be either Expressed Breast Milk (EBM), Donor Human Milk (DHM), formula, or a combination of EBM and formula or EBM and DHM. The volume of supplementation and duration of bottle use will be determined by the neonate's physician. The mother will return the neonate to their crib then pump and hand express after feeding sessions per the IBCLC's recommendation. The mother will document each feeding session in the feeding log provided at the bedside.
A radioactive mixture and a manufacturing method thereof are disclosed. The radioactive mixture ( 188 Re-MN/Lipiodol mixture) is formed by chelating reaction of MN series compounds that are amine-amide-disulfide amine quadric-dentate chelate ligands with TcO 4   − /or ReO 4   − , and then dissolved in Lipiodol. Moreover, the  99m Tc/or  188 Re of the TcO 4   − /or ReO 4   −  avoids bone marrow injuries caused by free  90 Y. By the feature of the Lipiodol that stays in liver tumors for a long period, the radioactive mixture is applied to treat liver cancers by injection so that injuries caused by surgical operations can be prevented.  188 Re-MN/Lipiodol is used for liver cancer, breast cancer or other solid tumors treatment. Re-188 MN or Re-188 MN/Lipiodol can be mixed with anticancer drugs, hydrogel, liposome, micelle or other nano-particles to form the multifunctional therapeutic modality.
FIELD: organic chemistry, chemical technology. SUBSTANCE: invention relates to the novel method of synthesis of isoxazolidinedione compound of the formula (II)   where R means optionally substituted aromatic hydrocarbon group or its salt by interaction of compound of the formula (1)   or its salt with compound of the formula (2)   in the presence of inorganic base in an aqueous solvent to yield aspartate compound of the formula (3)  . The latter interacts with acetic anhydride in the presence of dimethylaminopyridine as a catalyst and a base followed by heating for decarboxylation to yield compound of the formula (4)  . Then p- toluenesulfonic acid is added to compound (4) to synthesize oxazolylacetate derivative of the formula (5)   that is reduced further with tetrahydrofuran in the presence of NaBH 4  and methanol to oxazolylethanol derivative of the formula (6)   followed by further its interaction with mesylchloride in the presence of triethylamine to yield methanesulfonate derivative of the formula (7)   and the latter interacts with compound of the formula (8)   in the presence of potassium carbonate to yield benzylidene derivative of the formula (9)   and the latter is reduced in hydrogen atmosphere to yield derivative of malonic acid of the formula (10)   which then interacts with hydroxylamine in the presence of a base to yield compound of the formula (II). EFFECT: new method of synthesis of derivatives of isoxazolidinedione. 7 cl, 6 ex _
The study population consists of all consecutive women meeting inclusion/exclusion criteria and delivering at the Nîmes University Hospital, France during an inclusion period of 6 months. "Cases" are classified as those with a vaginal lesion due to delivery.
<P>PROBLEM TO BE SOLVED: To provide a liposome stabilizer capable of replacing a cholesterol or a cholesterol derivative, to provide a liposome containing the stabilizer and to provide a food containing the liposome.  <P>SOLUTION: The liposome stabilizer contains a plant sterol ester and/or phosphatidylserine as an active ingredient. The liposome contains the plant sterol ester and/or the phosphatidylserine in the liposome. The food contains the liposome and the plant sterol ester and/or the phosphatidylserine. The liposome can be stabilized to a degree nearly equal to the cholesterol by incorporating the plant sterol ester and/or the phosphatidylserine.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Many people with chronic stroke (PwCS) exhibit deficits in step width modulation, an important strategy for walking balance. A single exposure to swing leg perturbations can temporarily strengthen this modulation. The objective of this parallel, double-blinded, randomized controlled trial was to investigate whether repeated perturbations cause sustained increases in step modulation (NCT02964039; funded by the VA). 54 PwCS at the Medical University of South Carolina were randomly assigned to one of three intervention groups: Control (n = 18), with minimal forces; Assistive (n = 18), pushing the swing leg toward a mechanically appropriate location; Perturbing (n = 18), pushing the swing leg away from a mechanically appropriate location. All intervention groups included 24 training sessions over 12-weeks with up to 30-minutes of treadmill walking while interfaced with a novel force-field and a 12-week follow-up period, with five interspersed assessment sessions. Our primary outcome measure was paretic step width modulation, the partial correlation between step width and pelvis displacement (ρSW). Secondarily, we quantified swing and stance leg contributions to step modulation, clinical assessments of walking balance and confidence, and real-world falls. Outcomes were analyzed for participants who completed all assessment sessions (n = 44). Only the Perturbing group exhibited significant increases in paretic ρSW, which were present after 4-weeks of training and sustained through follow-up (t = 2.42-3.17). These changes were due to improved control of paretic swing leg positioning. However, perturbation-induced changes in step modulation were not always significantly greater than those in the Control group, and clinical assessments were similar across intervention groups. Participants in the Perturbing group experienced a lower fall rate than those in the Control group (incidence rate ratio = 0.53), although our small sample size warrants caution. The present results indicate that perturbations can cause sustained modifications of targeted biomechanical characteristics of post-stroke gait, although such changes alone may be insufficient to change more complex clinical assessments.
Apivirin is an antiviral drug extracted from the sickle bush berle tree, and is prepared from the following components: gallotannin, catechu tannin, alkaloids, flavonoids, saponins, anthocyanins, leucoanthocyanins, steroids and terpenoids, which together exhibit activity against COVID-19. It can be used for the treatment and prevention of coronavirus diseases in both symptomatic and asymptomatic patients as well as in all contactants. Toxicology tests on rats are conclusive and aspirin is non-toxic. In case of respiratory assistance, the starting dose is 12 capsules, each containing 350 mg (oral or intubated) of apivirin powder, obtained by adding 500 mg of pure lyophilized extract. The above doses were taken three times per day according to the half-life of apivirin (four hours). For less severe cases and asymptomatic cases, the dose was three times daily, three capsules each time; for prophylaxis, the dose is three times daily, one to two capsules at a time, and the uptake of apivirin leads to the disappearance of coronaviruses.
Peptides derived from three regions of the lectin binding region of GMP-140 have been found to selectively interact with "selectins", including GMP-140, ELAM-1, and lymphocyte homing receptor. The three regions include amino acids 19-34, 54-72, and 66-89, based on the numbers of the residues contained in the peptide, with residue 1 defined as the N terminus of the mature protein after cleavage of the signal peptide. Fucosylated sialyated lactosamine structures that bind to GMP-140 have also been discovered. The structure is created by expression of α(1,3) fucosyltransferases capable of modifying acceptors containing α(2,3) sialic acid-substituted lactosaminoglycans. Le x , Galβ1,4 (Fucα1,3)GlcNAcβ1-R (where R is a protein or other carbohydrate structure) forms the core of this sialyated structure. The peptides and carbohydrate structures are useful as diagnostics and for clinical applications in the modulation or inhibition of coagulation processes or inflammatory processes.
Dysphagia with aspiration is a common disorder in the pediatric population. Aspiration with feeds is diagnosed on modified barium swallow studies and patients are referred to the pediatric otolaryngologist to assess the airway for a possible laryngeal cleft. Type I laryngeal cleft can lead to dysphagia and aspiration in young children. However, diagnosis of type I laryngeal cleft can be difficult and subjective at microlaryngoscopy in the operating room. Type I laryngeal cleft evaluation and treatment in the pediatric population is an emerging science. The largest published series of pediatric patients with type I laryngeal clefts shows conflicting evidence in terms of outcomes, resolution of dysphagia and method of treatment. It is generally recommended to do an injection laryngoplasty at the time of airway evaluation as a diagnostic and therapeutic measure. Improvement in symptoms supports the diagnosis and can serve as either definitive treatment with repeated injections or as a preemptive treatment in preparation for surgical repair. A comparison of quality of life outcomes before and after injection laryngoplasty has not been carried out. Thus, the aim of this study is to determine if injection laryngoplasty improves symptoms and quality of life related to dysphagia in a pediatric population with laryngeal clefts.
Combination of CDDP at 75 mg/m2 (day 1) or CBDCA at Area Under the Curve=6 (AUC=6) (day 1) + PEM at 500 mg/m2 (day 1) will be administered to patients with non-squamous cell carcinoma at 3-week intervals. To those with squamous cell carcinoma, CBDCA at AUC=6 (day 1) + nab-PTX at 100 mg/m2 (days 1, 8, and 15) will be administered at 3-week intervals. If there is no progression after the 4th course of induction therapy, it will be switched to maintenance therapy. For maintenance therapy, the combination of PEM at 500 mg/m2 (day 1) + Pembrolizumab at 200 mg (day 1) will be administered to patients with non-squamous cell carcinoma at 3-week intervals. To those with squamous cell carcinoma, Pembrolizumab at 200 mg (day 1) will be administered at 3-week intervals until disease progression or intolerable toxicity. Pembrolizumab administration should be continued for 2 years involving induction and maintenance therapies or until the 35th course.
PURPOSE:A hair cosmetic, containing a phosphoric acid ester and a protein derivative and capable of imparting setting property to the hair without stickiness. CONSTITUTION:A hair cosmetic containing a phosphoric acid ester expressed by formula I (X is 1-8C straight-chain alkyl or glyceryl; Y is formula II or Z; R is H or methyl; Z is H, alkali metal, alkyl-substituted ammonium, etc.; n is 0-100) and a protein derivative, e.g. a polypeptide obtained by hydrolyzing collagen protein or an ester thereof. The use of the above-mentioned compounds expressed by formulas I and II in the above-mentioned hair cosmetic provides finish without stickiness and has effect on ready collection of the hair because of improved setting property thereof. The hair cosmetic is useful for various applications, including rinse and treatment. Both compounds are preferably used together at 95:5-5:95 weight ratio of the phosphoric acid ester to the protein derivative.
Mental stress ischemia occurs when a psychosocial or mental stressor triggers an imbalance between the supply and demand for oxygen by cardiac myocytes. Epidemiological studies indicate that mental stress ischemia is common, occurring in 20-25% of patients with coronary artery disease (CAD) and portends a poor prognosis. The underlying mechanisms are thought to involve stress-induced activation of the sympathetic nervous system and associated effects on cardiovascular function. But how neurobiological and cardiovascular factors interact to generate mental stress ischemia is unknown. Furthermore, patients with major depressive disorder, bipolar disorder, and other stress-related psychiatric conditions have elevated rates of cardiovascular co-morbidities, including sudden cardiac death, yet mental stress ischemia has not been studied extensively in these psychiatric populations. The purpose of project is to answer fundamental questions about the mechanisms underlying mental stress ischemia in patients with coronary artery disease, mood disorders, or both, and to identify potential biomarkers and psychosocial risk factors associated with this condition.

To achieve this goal, investigators will use cutting-edge cardiovascular and functional neuroimaging tools to study mental stress ischemia in a carefully controlled laboratory setting in subjects recruited from four patient populations: 1) patients who recently sustained a myocardial infarction; 2) patients undergoing non-emergent invasive coronary angiography (with and without known coronary artery disease); 3) patients with a diagnosis of major depressive disorder; and 4) patients with a diagnosis of bipolar 1 or bipolar 2 disorder.
OBJECTIVE: To analyze the effect of phonation in a glass tube immersed in water compared to other interventions on general degree of vocal deviation, fundamental frequency, sound pressure level, and vocal self-assessment in vocally healthy individuals.
METHODS: This is a systematic review and meta-analysis developed from the research question: "In vocally healthy individuals, what is the effect of phonation into a glass tube immersed in water versus other vocal interventions, other activities, or no intervention on general degree of vocal deviation, fundamental frequency, sound pressure level, and vocal self-assessment?" An electronic search was performed using Medline, LILACS, Cochrane Library, Embase, Web of Science, and SCOPUS databases, and a manual search was performed in the gray literature (Brazilian Digital Library of Theses and Dissertations and OpenGrey), the Journal of Voice, and the citations of the studies. Studies with (P) population of adults with healthy voices, (I) intervention with phonation into a glass tube immersed in water, (C) comparison with other vocal interventions, other activities, or no intervention, (O) outcomes of the general degree of vocal deviation, fundamental frequency, sound pressure level, and vocal self-assessment, and an (S) study with the experimental or quasi-experimental design were included. Risk of bias assessment and meta-analysis of the outcomes were performed.
RESULTS: A total of 457 studies were found in the search; four were selected for the systematic review and meta-analysis. In the risk of bias assessment, there was an uncertain risk of selection and performance bias in 100% of the studies and uncertain risk of detection bias of 75%. All studies had an experimental design, and most of them were conducted on women. In the fundamental frequency analysis, there was no difference between the effect sizes of the interventions (z = 0.471, P = 0.638). In the vocal self-assessment, the estimated odds ratio was 1.31, showing a greater chance of improvement in the intervention group than with the comparison group (z = 3.45, P < 0.001). There were not enough studies to analyze the general degree of vocal deviation and sound pressure level outcomes.
CONCLUSION: Phonation into a glass tube immersed in water has a greater positive effect on vocal self-assessment than other interventions in vocally healthy individuals.
Absorption: Fondaparinux sodium administered by subcutaneous injection is rapidly and completely absorbed (absolute bioavailability is 100%). Following a single subcutaneous dose of fondaparinux sodium 2.5 mg in young male subjects, Cmax of 0.34 mg/L is reached in approximately 2 hours. In patients undergoing treatment with fondaparinux sodium injection 2.5 mg, once daily, the peak steady-state plasma concentration is, on average, 0.39 to 0.50 mg/L and is reached approximately 3 hours post-dose. In these patients, the minimum steady-state plasma concentration is 0.14 to 0.19 mg/L. In patients with symptomatic deep vein thrombosis and pulmonary embolism undergoing treatment with fondaparinux sodium injection 5 mg (body weight <50 kg), 7.5 mg (body weight 50 to 100 kg), and 10 mg (body weight >100 kg) once daily, the body-weight-adjusted doses provide similar mean steady-state peaks and minimum plasma concentrations across all body weight categories. The mean peak steady-state plasma concentration is in the range of 1.20 to 1.26 mg/L. In these patients, the mean minimum steady-state plasma concentration is in the range of 0.46 to 0.62 mg/L.  
  
Distribution: In healthy adults, intravenously or subcutaneously administered fondaparinux sodium distributes mainly in blood and only to a minor extent in extravascular fluid as evidenced by steady state and non-steady state apparent volume of distribution of 7 to 11 L. Similar fondaparinux distribution occurs in patients undergoing elective hip surgery or hip fracture surgery. In vitro, fondaparinux sodium is highly (at least 94%) and specifically bound to antithrombin III (ATIII) and does not bind significantly to other plasma proteins (including platelet Factor 4 [PF4]) or red blood cells.  
  
Metabolism: In vivo metabolism of fondaparinux has not been investigated since the majority of the administered dose is eliminated unchanged in urine in individuals with normal kidney function.  
  
Elimination: In individuals with normal kidney function, fondaparinux is eliminated in urine mainly as unchanged drug. In healthy individuals up to 75 years of age, up to 77% of a single subcutaneous or intravenous fondaparinux dose is eliminated in urine as unchanged drug in 72 hours. The elimination half-life is 17 to 21 hours.